偷窥 性别 瘾 xxxxx,声声奶酥1v办公室,性色av蜜桃av人妻无码,欧洲精品99毛片免费高清观看

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

產(chǎn)品分類

聯(lián)系我們

聯(lián)系人:蔣經(jīng)理
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73196KIF5B(E15)-RET(E12) V804M/BaF3

KIF5B(E15)-RET(E12) V804M/BaF3
名稱 KIF5B(E15)-RET(E12) V804M/BaF3
型號(hào) CBP73196
報(bào)價(jià)
特點(diǎn) KIF5B(E15)-RET(E12) [V804M]/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO
  • 詳細(xì)內(nèi)容
CBP73196
I. Introduction

Cell Line Name:

KIF5B(E15)-RET(E12) [V804M]/BaF3

Host Cell:

BA/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RRPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of  KIF5B-RET [V804M]/BaF3

CBP73196 WB.png


2. Sanger of KIF5B-RET [V804M]/BaF3

CBP73196 sanger1.png

CBP73196 sanger2.png


3. Anti-proliferation assay


CBP73196 fig.jpg

Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret(S) V804M Cells (C1).




如果你對(duì)CBP73196KIF5B(E15)-RET(E12) V804M/BaF3感興趣,想了解更詳細(xì)的產(chǎn)品信息,填寫下表直接與廠家聯(lián)系:


留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細(xì)地址:

  • 補(bǔ)充說明:

  • 驗(yàn)證碼:

    請(qǐng)輸入計(jì)算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
做爰视频试看30分钟| 久久久久久久| 18禁免费吃奶摸下激烈视频| 绝味儿媳妇txt| 裸体跳舞xxxx裸体跳舞| 好吊妞| 婷婷丁香五月| 亚洲精品久久久口爆吞精| 同性两个17男互摸互吃的小说| 欧美+日韩+国产| 国产丰满成熟女人性满足视频| 中文无码亚洲色偷偷a片| 男男做a爱过程免费视频| 我和亲妺妺乱的性视频| 国产国产乱老熟女视频网站97| 两女女百合互慰av赤裸无遮挡| 男男惩罚羞耻双腿分打屁股小作文| 去部队探亲一晚上几次| 亚洲中文字幕无码自拍一拍五月| 清冷医生受h打开腿乖听话男男| 高洁在公车被灌满jing液| 免费观看黄网站| 高清欧美性猛交xxxx黑人猛交| 久久九九久精品国产免费直播| 没带罩子让他捏了一节课| h网站| 挺进同学熟妇的身体| 苍井空浴缸大战猛男120分钟| 对付老公出轨最狠的一招| 闺蜜男友猛撞h花液h深| 一本加勒比hezyo东京热高清| 精品人妻人人做人人爽| 免费三级网站| 白白嫩嫩又小又紧| japan少妇洗澡videos| 办公室扒开奶罩揉吮奶头a片| 亚洲gv猛男gv无码男同短文| 少妇与大狼拘作爱性a片| 亚洲区色情区激情区小说| 撑开毛都没长齐的小缝| 欧美熟妇vivoe精品|